Please login to the form below

Not currently logged in


This page shows the latest Immunocore news and features for those working in and with pharma, biotech and healthcare.

Christina Coughlin to leave Immunocore for Tmunity

Christina Coughlin to leave Immunocore for Tmunity

Christina Coughlin to leave Immunocore for Tmunity. UPenn pioneers building their own biotech company. ... The departure of Coughlin will be another loss for Immunocore, meanwhile, as it CEO Eliot Forster left the company in February.

Latest news

More from news
Approximately 7 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • 30 Women Leaders in UK Healthcare (part 2)

    Officer at Immunocore (since 2013), one of the most hotly-tipped UK biotech companies in the field of immunotherapy. ... and GlaxoSmithKline have each signed significant strategic discovery deals during Eva-Lotta’s five years at Immunocore.

  • Pharma deals in July 2015 Pharma deals in July 2015

    This month, Immunocore which develops T-cell receptor based drugs and has a lead product in Phase IIa, raised $320m (£205m) via a private financing round from a syndicate of investors, ... It is hoped that Immunocore and Mereo are signs that at long

  • Pharma deals in March 2015 Pharma deals in March 2015

    Sir John Bell, Regius Professor of Medicine at Oxford University and a non-executive director of Immunocore has criticised the City of London for failing to provide financial support to life

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    30. Immunocore/ Eli Lilly. Co-discovery /co-development, options (cost/profit share). ImmTAC (Immune mobilising mTCR Against Cancer) technology (discovery).

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    Other deals include an alliance with the UK biotech Immunocore via AZ's MedImmune subsidiary and an expansion of an existing personalised drug partnership with Horizon Discovery. “

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

  • Immunocore appoints chief financial officer Immunocore appoints chief financial officer

    Oxford, UK-based Immunocore has appointed Paul Fry as its chief financial officer. ... As Immunocore continues to grow we are continually looking for outstanding individuals such as Paul to complement our team.

  • Immunocore names CEO Immunocore names CEO

    The UK-based biotech Immunocore has appointed industry veteran Dr Eliot Forster as CEO. ... His significant drug development experience will be invaluable to Immunocore as we continue to deliver within our partnerships and advance our proprietary ImmTAC

More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....